FR3051197B1 - Particule virale pour le transfert d'arns dans les cellules impliquees dans la reponse immune - Google Patents

Particule virale pour le transfert d'arns dans les cellules impliquees dans la reponse immune Download PDF

Info

Publication number
FR3051197B1
FR3051197B1 FR1654333A FR1654333A FR3051197B1 FR 3051197 B1 FR3051197 B1 FR 3051197B1 FR 1654333 A FR1654333 A FR 1654333A FR 1654333 A FR1654333 A FR 1654333A FR 3051197 B1 FR3051197 B1 FR 3051197B1
Authority
FR
France
Prior art keywords
rna
transfer
immune response
viral particle
cells involved
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR1654333A
Other languages
English (en)
Other versions
FR3051197A1 (fr
Inventor
Pascale Bouille
Christine Duthoit
Lucille Lamouroux
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
VECTALYS
Original Assignee
VECTALYS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR1654333A priority Critical patent/FR3051197B1/fr
Application filed by VECTALYS filed Critical VECTALYS
Priority to CN201780043718.0A priority patent/CN109562150A/zh
Priority to PCT/FR2017/051165 priority patent/WO2017194903A2/fr
Priority to AU2017263138A priority patent/AU2017263138B2/en
Priority to EP17730842.6A priority patent/EP3454889A2/fr
Priority to US16/301,354 priority patent/US11371059B2/en
Priority to CA3023788A priority patent/CA3023788A1/fr
Priority to SG11201810014UA priority patent/SG11201810014UA/en
Priority to JP2018559309A priority patent/JP6916209B2/ja
Publication of FR3051197A1 publication Critical patent/FR3051197A1/fr
Priority to IL262944A priority patent/IL262944A/en
Application granted granted Critical
Publication of FR3051197B1 publication Critical patent/FR3051197B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/85—Fusion polypeptide containing an RNA binding domain
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16051—Methods of production or purification of viral material
    • C12N2740/16052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/18011—Details ssRNA Bacteriophages positive-sense
    • C12N2795/18111—Leviviridae
    • C12N2795/18122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/24—Vectors characterised by the absence of particular element, e.g. selectable marker, viral origin of replication
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/50—Vectors for producing vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention se rapporte à une particule rétrovirale comportant une protéine issue de la polyprotéine Gag, une protéine d'enveloppe, optionnellement une intégrase et au moins deux ARN non viraux encapsidés, les ARN non viraux encapsidés comportant chacun une séquence d'ARN d'intérêt liée à une séquence d'encapsidation, chaque séquence d'encapsidation étant reconnue par un domaine de liaison introduit dans la protéine issue de la polyprotéine Gag et/ou dans l'intégrase, et l'une au moins dédites séquences d'intérêt des ARN non viraux encapsidés comporte une partie codant pour au moins un épitope et/ou au moins une structure moléculaire reconnaissant spécifiquement un épitope.
FR1654333A 2016-05-13 2016-05-13 Particule virale pour le transfert d'arns dans les cellules impliquees dans la reponse immune Active FR3051197B1 (fr)

Priority Applications (10)

Application Number Priority Date Filing Date Title
FR1654333A FR3051197B1 (fr) 2016-05-13 2016-05-13 Particule virale pour le transfert d'arns dans les cellules impliquees dans la reponse immune
JP2018559309A JP6916209B2 (ja) 2016-05-13 2017-05-12 特に免疫応答に関与する細胞への、ｒｎａの転移のためのウイルス粒子
AU2017263138A AU2017263138B2 (en) 2016-05-13 2017-05-12 Viral particle for RNA transfer, especially into cells involved in immune response
EP17730842.6A EP3454889A2 (fr) 2016-05-13 2017-05-12 Particule virale pour le transfert d'arns, notamment dans les cellules impliquées dans la réponse immune
US16/301,354 US11371059B2 (en) 2016-05-13 2017-05-12 Viral particle for the transfer of RNAs, especially into cells involved in immune response
CA3023788A CA3023788A1 (fr) 2016-05-13 2017-05-12 Particule virale pour le transfert d'arns, notamment dans les cellules impliquees dans la reponse immune
CN201780043718.0A CN109562150A (zh) 2016-05-13 2017-05-12 用于将rna转移到尤其参与免疫应答的细胞中的病毒颗粒
PCT/FR2017/051165 WO2017194903A2 (fr) 2016-05-13 2017-05-12 Particule virale pour le transfert d'arns, notamment dans les cellules impliquées dans la réponse immune
SG11201810014UA SG11201810014UA (en) 2016-05-13 2017-05-12 Viral particle for rna transfer, especially into cells involved in immune response
IL262944A IL262944A (en) 2016-05-13 2018-11-12 A viral particle for RNA transfer, especially to cells involved in the immune response

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1654333A FR3051197B1 (fr) 2016-05-13 2016-05-13 Particule virale pour le transfert d'arns dans les cellules impliquees dans la reponse immune

Publications (2)

Publication Number Publication Date
FR3051197A1 FR3051197A1 (fr) 2017-11-17
FR3051197B1 true FR3051197B1 (fr) 2023-09-08

Family

ID=57583128

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1654333A Active FR3051197B1 (fr) 2016-05-13 2016-05-13 Particule virale pour le transfert d'arns dans les cellules impliquees dans la reponse immune

Country Status (1)

Country Link
FR (1) FR3051197B1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114616336A (zh) * 2019-09-20 2022-06-10 博德研究所 用于将货物递送至靶细胞的组合物和方法

Also Published As

Publication number Publication date
FR3051197A1 (fr) 2017-11-17

Similar Documents

Publication Publication Date Title
CY1124518T1 (el) Μεταλλαγες πρωτεϊνης φακελου hiv που σταθεροποιουν το τριμερες
CY1124664T1 (el) Υποδοχεις τ λεμφοκυτταρων
Popik et al. Human immunodeficiency virus type 1 uses lipid raft-colocalized CD4 and chemokine receptors for productive entry into CD4+ T cells
CY1124182T1 (el) Αντισωματα anti-tmprss2 και θραυσματα δεσμευσης αντιγονου
CY1124364T1 (el) Μεθοδοι για την ανιχνευση aav
MX2024001190A (es) Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco.
Okuya et al. Multiple routes of antibody-dependent enhancement of SARS-CoV-2 infection
MX2018012268A (es) Receptores de celulas t.
BR112017007202A2 (pt) receptores de célula t
RU2022106357A (ru) Противораковые рнк-вакцины
MX2020006764A (es) Una proteína de la cápside de raav modificada para terapia génica.
AR105026A1 (es) ANTICUERPOS MADURADOS POR AFINIDAD Y HUMANIZADOS PARA FcRH5 Y MÉTODOS PARA SU USO
WO2017066764A3 (fr) Modification de la région n-terminale des protéines de capsides pour améliorer les propriétés des virus adéno-associés
MA44179B1 (fr) Compositions comprenant un virus adeno-associe exprimant des constructions a double anticorps et leurs utilisations
EA202091844A1 (ru) Композиции аденоассоциированных вирусов для переноса гена pah и способы их применения
WO2015112558A3 (fr) Peptides, dispositifs et procédés pour la détection d'anticorps d'anaplasma
EA201991876A1 (ru) Антитела против фактора d и их применения
PH12020500025A1 (en) Trimer stabilizing hiv envelope protein mutations
FR3051197B1 (fr) Particule virale pour le transfert d'arns dans les cellules impliquees dans la reponse immune
WO2017194903A8 (fr) Particule virale pour le transfert d'arns, notamment dans les cellules impliquées dans la réponse immune
MX2022000551A (es) Proteínas de la cápside de aav modificadas para el tratamiento de una enfermedad artrítica.
JOP20220043A1 (ar) بروتين كابسيد vp1 معدل معزول من aav5
WO2017194902A3 (fr) Particule pour l'encapsidation d'un système d'ingénierie du génome
EA201890187A1 (ru) Рекомбинантные вирусоподобные частицы (vlp) с использованием протеина группового антигена (gag) вируса бычьего иммунодефицита
FR3051196B1 (fr) Particule pour l'encapsidation d'un systeme d'ingenierie du genome

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20171117

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 6

PLFP Fee payment

Year of fee payment: 7

PLFP Fee payment

Year of fee payment: 8

PLFP Fee payment

Year of fee payment: 9